August 22, 2025

Nemolizumab Study Tracks 68 Weeks of Relief

A long-term clinical study finds that the biologic therapy nemolizumab, when used with topical corticosteroids, continues to improve itch, sleep, and skin symptoms in prurigo nodularis patients over 68 weeks.

Conexiant

August 22, 2025

Linear Hyperpigmentation After Chemotherapy: What's Your Diagnosis?

A 15-year-old girl developed distinctive, painless, whip-like streaks across her trunk and back after receiving combination chemotherapy for ovarian yolk sac tumor. What’s your diagnosis?

Conexiant

August 21, 2025

Medical Oddities: Puberty’s Hidden Fine Print

Puberty timing, feline brains, tea habits, sweat patches, and stings unite in this week’s medical grab bag.

Conexiant

August 14, 2025

Dalbavancin Holds Its Own Against S. aureus Bacteremia, Study

"All treatments currently approved with an indication for bacteremia require prolonged intravenous access."

Conexiant

August 14, 2025

Thai Trial Tests Turmeric Emulgel Skin Safety

Thai investigators test a botanical emulgel formulation to identify early safety signals related to skin irritation and allergenicity before advancing to patient trials.

Conexiant

August 08, 2025

Mental Health Risk High in Patients with Hidradenitis Suppurativa

Hidradenitis suppurativa is associated with increased risks of depression and anxiety across all treatment levels, highlighting the importance of proactive psychiatric screening in dermatologic care.

Conexiant

August 07, 2025

PsA Patients Accurately Report Nonjoint Symptoms

Patients with psoriatic arthritis consistently identify nonjoint symptoms such as dactylitis, psoriasis, and uveitis, demonstrating the clinical utility of patient-reported outcome measures.

Conexiant

August 06, 2025

Bimekizumab Sustains Psoriasis Response for 3 Years

A 3-year analysis of a phase IIIb trial found that bimekizumab, a dual interleukin-17A and interleukin-17F inhibitor, maintained high rates of skin clearance and demonstrated a consistent safety profile in patients with moderate-to-severe plaque psoriasis, including those who switched from secukinumab, an interleukin-17A inhibitor.

Conexiant

August 05, 2025

What Do Patients Look for in Health Care Facilities?

An analysis of online reviews of health care facilities identified language patterns associated with positive or negative patient experiences.

Conexiant